Metastatic Lung Cancer Research Reveals Immunotherapy Breakthroughs

Strategic Insights -

Researchers from the First Affiliated Hospital of Zhengzhou University have discovered that immunotherapy can be enhanced to treat metastatic lung cancer. The study, published in Cancer Immunology, Immunotherapy, found that tumor-associated macrophages (TAMs) contribute to immune suppression in lung cancer by limiting the activation of CD8 T cells and cytokine production. The researchers also identified secreted phosphoprotein 1 (SPP1) as a key factor in the development of brain metastatic tumors.

Key Takeaways:

  • The study demonstrated that immunotherapy can be effective in treating metastatic lung cancer, particularly when combined with anti-SPP1 treatment.
  • Tumor-associated macrophages (TAMs) contribute to immune suppression in lung cancer by limiting the activation of CD8 T cells and cytokine production.
  • SPP1 overexpression in macrophages enhanced their immunosuppressive phenotype by upregulating CD73 and cytokines such as IL-10 and TGF-b, leading to impaired CD8 T cell function via A2AR signaling.
  • Anti-SPP1 treatment positively impacted CD8 T cell function, counteracting SPP1-induced dysfunction and facilitating the production of cytokines.
  • The study found that the proportions of immune cells in metastatic brain tissues are lower, while the infiltration of macrophages is higher.

Statistics:

  • 74.10: The issue volume number of the journal Cancer Immunology, Immunotherapy where the study was published.
  • 319: The page number of the study in Cancer Immunology, Immunotherapy.
  • 450002: The zip code of the location of the First Affiliated Hospital of Zhengzhou University.
  • 34: The number of authors listed in the study, including Tengyue Zhang, Rahma Taher Almgrami, Qitai Zhao, Mingming You, Jinyan Liu, and Yi Zhang.

Sources:

  • Cancer Immunology, Immunotherapy. 2025;74(10):319.
  • Springer. One New York Plaza, Suite 4600, New York, NY, United States. (www.springer.com; www.springerlink.com/content/0340-7004/)
  • First Affiliated Hospital of Zhengzhou University. Biotherapy Center & Cancer Center, Zhengzhou, 450002, Henan, People's Republic of China.